Antibody-mediated Control Mechanisms of Viral Infections

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2024 Aug 20

PMID 39162394

Authors

Samantha R Mackin

Alan Sariol

Michael S Diamond

Affiliations

Soon will be listed here.

Abstract

Antibodies generated after vaccination or natural pathogen exposure are essential mediators of protection against many infections. Most studies with viruses have focused on antibody neutralization, in which protection is conferred by the fragment antigen binding region (Fab) through targeting of different steps in the viral lifecycle including attachment, internalization, fusion, and egress. Beyond neutralization, the fragment crystallizable (Fc) region of antibodies can integrate innate and adaptive immune responses by engaging complement components and distinct Fc gamma receptors (FcγR) on different host immune cells. In this review, we discuss recent advances in our understanding of antibody neutralization and Fc effector functions, and the assays used to measure them. Additionally, we describe the contexts in which these mechanisms are associated with protection against viruses and highlight how Fc-FcγR interactions can improve the potency of antibody-based therapies.

References

Fan W, Zhang D, Qian P, Qian S, Wu M, Chen H . Swine TRIM21 restricts FMDV infection via an intracellular neutralization mechanism. Antiviral Res. 2016; 127:32-40. DOI: 10.1016/j.antiviral.2016.01.004. View

Bruhns P, Jonsson F . Mouse and human FcR effector functions. Immunol Rev. 2015; 268(1):25-51. DOI: 10.1111/imr.12350. View

van Osch T, Nouta J, Derksen N, van Mierlo G, van der Schoot C, Wuhrer M . Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation. J Immunol. 2021; 207(6):1545-1554. PMC: 8428746. DOI: 10.4049/jimmunol.2100399. View

Tao M, Morrison S . Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989; 143(8):2595-601. View

Parekh B, Berger E, Sibley S, Cahya S, Xiao L, LaCerte M . Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs. 2012; 4(3):310-8. PMC: 3355484. DOI: 10.4161/mabs.19873. View

SZMUNESS W, Stevens C, Harley E, Zang E, Oleszko W, William D . Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980; 303(15):833-41. DOI: 10.1056/NEJM198010093031501. View

Aleman O, Mora N, Rosales C . The Antibody Receptor Fc Gamma Receptor IIIb Induces Calcium Entry Transient Receptor Potential Melastatin 2 in Human Neutrophils. Front Immunol. 2021; 12:657393. PMC: 8155622. DOI: 10.3389/fimmu.2021.657393. View

Bracher M, Gould H, Sutton B, Dombrowicz D, Karagiannis S . Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods. 2007; 323(2):160-71. DOI: 10.1016/j.jim.2007.04.009. View

Schlothauer T, Herter S, Koller C, Grau-Richards S, Steinhart V, Spick C . Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016; 29(10):457-466. DOI: 10.1093/protein/gzw040. View

10.

Gomes Mourao M, Bastos M, de Figueiredo R, Gimaque J, Galusso E, Kramer V . Mayaro fever in the city of Manaus, Brazil, 2007-2008. Vector Borne Zoonotic Dis. 2011; 12(1):42-6. PMC: 3249893. DOI: 10.1089/vbz.2011.0669. View

11.

Porter R . A chemical study of rabbit antiovalbumin. Biochem J. 1950; 46(4):473-8. PMC: 1275450. DOI: 10.1042/bj0460473. View

12.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

13.

Porter R . The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J. 1959; 73:119-26. PMC: 1197021. DOI: 10.1042/bj0730119. View

14.

Laver W, Air G, Webster R . Mechanism of antigenic drift in influenza virus. Amino acid sequence changes in an antigenically active region of Hong Kong (H3N2) influenza virus hemagglutinin. J Mol Biol. 1981; 145(2):339-61. DOI: 10.1016/0022-2836(81)90209-6. View

15.

Starbeck-Miller G, Badovinac V, Barber D, Harty J . Cutting edge: Expression of FcγRIIB tempers memory CD8 T cell function in vivo. J Immunol. 2013; 192(1):35-9. PMC: 3874719. DOI: 10.4049/jimmunol.1302232. View

16.

Pierre C, Adams L, Higgins J, Anasti K, Goodman D, Mielke D . Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLoS Pathog. 2024; 20(6):e1011569. PMC: 11218955. DOI: 10.1371/journal.ppat.1011569. View

17.

Li D, Edwards R, Manne K, Martinez D, Schafer A, Alam S . In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021; 184(16):4203-4219.e32. PMC: 8232969. DOI: 10.1016/j.cell.2021.06.021. View

18.

McNamara R, Maron J, Boucau J, Roy V, Webb N, Bertera H . Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. mBio. 2023; 14(4):e0090223. PMC: 10470538. DOI: 10.1128/mbio.00902-23. View

19.

Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I . Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011; 108(31):12669-74. PMC: 3150898. DOI: 10.1073/pnas.1108455108. View

20.

Damelang T, de Taeye S, Rentenaar R, Roya-Kouchaki K, de Boer E, Derksen N . The Influence of Human IgG Subclass and Allotype on Complement Activation. J Immunol. 2023; 211(11):1725-1735. PMC: 10656437. DOI: 10.4049/jimmunol.2300307. View